Wright Medical Group Inc  

(Public, NASDAQ:WMGI)   Watch this stock  
Find more results for WMGI
24.64
-0.10 (-0.40%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.45 - 25.00
52 week 18.11 - 25.08
Open 24.83
Vol / Avg. 358,436.00/298,827.00
Mkt cap 1.15B
P/E 113.44
Div/yield     -
EPS 0.22
Shares 46.70M
Beta 0.80
Inst. own 99%
Aug 1, 2013
Q2 2013 Wright Medical Group, Inc. Earnings Conference Call - 4:30PM EDT - Add to calendar
Aug 1, 2013
Q2 2013 Wright Medical Group, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Apr 30, 2013
Q1 2013 Wright Medical Group, Inc. Earnings Conference Call
Feb 21, 2013
Q4 2012 Wright Medical Group, Inc. Earnings Conference Call
Feb 21, 2013
Q4 2012 Wright Medical Group, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 7.01% 1.09%
Operating margin 6.84% 4.99%
EBITD margin - 11.23%
Return on average assets 3.12% 0.62%
Return on average equity 5.53% 1.07%
Employees 1,400 -
Carbon Disclosure Rating - -

Address

5677 Airline Road
ARLINGTON, TN 38002
United States - Map
+1-901-8679971 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Wright Medical Group, Inc., through Wright Medical Technology, Inc. (WMT) and other operating subsidiaries (Wright), is a global orthopaedic medical device company specializing in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company is provider of surgical solutions for the foot and ankle market. It offers products in four primary market sectors: extremity reconstruction, biologics, knee reconstruction and hip reconstruction. Reconstructive devices are used to replace or repair knee, hip and other joints and bones that have deteriorated or have been damaged through disease or injury. Biologics are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. In March 2013, it completed acquisition of BioMimetic Therapeutics, Inc.

Officers and directors

David D. Stevens Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Robert J. Palmisano President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Lance A. Berry Chief Financial Officer, Senior Vice President,
Age: 38
Bio & Compensation  - Reuters
Timothy E. Davis Jr. President - OrthoRecon
Age: 41
Bio & Compensation  - Reuters
Eric A. Stookey President - Extremities
Age: 41
Bio & Compensation  - Reuters
Pascal Girin Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Daniel Garen Senior Vice President, Chief Compliance Officer
Age: 39
Bio & Compensation  - Reuters
James A. Lightman Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Edward A. Steiger Senior Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
William L. Griffin Jr. Senior Vice President - Global Operations
Age: 63
Bio & Compensation  - Reuters